| http://www.w3.org/ns/prov#value | - Dr. Petersen also questioned the validity of using a composite scale such as the CDR-SB suggested by the FDA, particularly for patients with mild cognitive impairment in whom, in his opinion, the test may be insensitive in picking up subtle changes of the disease. ???It may not be the best clinical marker in that stage of the disease,??? he said.
|
